Journal of the Formosan Medical Association
Volume 105, Issue 5 , Pages 377-383, 2006

Pericardial Fluid and Serum Levels of Vascular Endothelial Growth Factor and Endostatin in Patients With or Without Coronary Artery Disease

  • Jer-Young Liou
    • ,
  • Pei-Liang Kuan

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr. Pei-Liang Kuan, Division of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chang Road, Taipei 111, Taiwan
  • Kou-Gi Shyu

      Affiliations

    • Department of Education and Research, Taipei, Taiwan
    • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan
    • ,
  • Ming-Jen Lu

      Affiliations

    • Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
    • ,
  • Hung-Hsin Chao

      Affiliations

    • Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
    • ,
  • Bao-Wei Wang

      Affiliations

    • Department of Education and Research, Taipei, Taiwan

Division of Cardiology, Taipei, Taiwan

Received 7 July 2005; received in revised form 18 August 2005; accepted 4 October 2005.

Article Outline

Background/Purpose

Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients with or without ischemic heart disease.

Methods

A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15 patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled. In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay.

Results

The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs. 143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A (100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups A and B.

Conclusion

Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor collateralization in patients with coronary artery disease.

Key Words:  collateral circulation , coronary artery disease , endostatin , vascular endothelial growth factor

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Coats AJS . Pericardial fluid-dispensable or indispensable fluid and an example of patentable biodiversity . Int J Cardiol . 2001;77:109–111
  2. Fujita M , Komeda M , Hasegawa K , et al.   Pericardial fluid as a new material for clinical heart research . Int J Cardiol . 2001;77:113–118
  3. O'Reilly MS , Boehm T , Shing Y , et al.   Endostatin: an endogenous inhibitor of angiogenesis and tumor growth . Cell . 1997;88:277–285
  4. Yoon SS , Eto H , Lin CM , et al.   Mouse endostatin inhibits the formation of lung and liver metastasis . Cancer Res . 1999;59:6251–6256
  5. Perletti G , Concari P , Giardini RJ , et al.   Anti-tumor activity of endostatin against carcinogen-induced rat primary mammary tumors . Cancer Res . 2000;60:1793–1796
  6. Yokoyama Y , Green JE , Sukhatme VP , et al.   Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model . Cancer Res . 2000;60:4362–4365
  7. Ding I , Sun JZ , Fenton B , et al.   Intramural administration of endostatin plasmid inhibits vascular growth and perfusion in Mca-4 murine mammary carcinomas . Cancer Res . 2001;61:526–531
  8. Dixelius J , Larrson H , Sasaki T , et al.   Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis . Blood . 2000;95:3403–3411
  9. Dhar DK , Ono T , Yamanoi A , et al.   Serum endostatin predicts tumor vascularity in hepatocellular carcinoma . Cancer . 2002;95:2188–2195
  10. Bono P , Teeerenhovi L , Joensuu H . Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma . Cancer . 2003;97:2767–2775
  11. Zhao J , Yan F , Ju H , et al.   Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer . Cancer Lett . 2004;204:87–95
  12. Shweiki D , Itin A , Soffer D , et al.   Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis . Science . 1992;359:843–845
  13. Plate KH , Breier G , Weich HA , et al.   Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo . Nature . 1992;359:845–848
  14. Lee SH , Wolf PL , Escudero R , et al.   Early expression of angiogenesis factors in acute myocardial ischemia and infarction . N Engl J Med . 2000;342:626–633
  15. Kranz-Rau C , Kochs M , Waltenberger J . Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance . J Mol Cell Cardiol . 2000;32:65–72
  16. Panchal VR , Rehman J , Nguyen AT , et al.   Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease . J Am Coll Cardiol . 2004;43:1383–1387
  17. Rentrop KP , Cohen M , Blanke H , et al.   Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects . J Am Coll Cardiol . 1985;5:587–592
  18. Blann AD , Belgore FM , McCollum CN , et al.   Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes . Clin Sci . 2002;102:187–194
  19. Gerrah R , Tshori S , Gilon D . Pericardial fluid and serum VEGF in response to different types of heparin treatment . Int J Cardiol . 2004;94:193–196
  20. Losordo DW , Vale PR , Symes JF , et al.   Therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia . Circulation . 1998;98:2800–2804
  21. Hojo Y , Ikeda U , Zhu Y , et al.   Expression of vascular endothelial growth factor in patients with acute myocardial infarction . J Am Coll Cardiol . 2000;35:968–973
  22. Chilian WM , Mass HJ , Williams SE , et al.   Microvascular occlusions promote collateral growth . Am J Physiol . 1990;258:H1103–H1111
  23. Weihrauch D , Tessmer J , Wartier  , et al.   Repetitive coronary artery occlusion induce release of growth factors into the myocardial interstitium . Am J Physiol . 1998;275:H969–H976
  24. Alber HF , Frick M , Dulak J , et al.   Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease . Heart . 2005;91:365–366
  25. Zachary I , Mathur A , Yla-Herttuala S , et al.   Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor . Arterioscler Thromb Vasc Biol . 2000;20:1512–1520
  26. Fujita M , Ikemoto M , Kishishita M , et al.   Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina . Circulation . 1996;94:610–613
  27. Ikonomidis I , Andreotti F , Economou E , et al.   Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin . Circulation . 1997;96:3542–3548
  28. Schaper W , Ito W . Molecular mechanisms of coronary collateral vessel growth . Circ Res . 1996;79:911–919

PII: S0929-6646(09)60133-9

doi:10.1016/S0929-6646(09)60133-9

Journal of the Formosan Medical Association
Volume 105, Issue 5 , Pages 377-383, 2006

Article Tools